Under the terms of the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003, Medicare, for the most part, reimburses hospitals for the cost of outpatient treatment with SIR-Spheres® Y-90 resin microspheres.

Many private payers also acknowledge the clinical utility of the SIRT procedure and have issued positive coverage policies for treatment. These payers include Aetna, Anthem, Cigna, Healthnet, Humana, United Healthcare, Wellpoint, and many independent Blue Cross/Blue Shield plans, as well as many other smaller plans on a case-by-case basis.

Please see the 2020 Coding Guide for more information.

Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.